Investigational drug · Phase 2
ENV-294
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis (AD), Atopic Dermatitis, Asthma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "ENV-294"
First trial start
2025
Dec 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ENV-294", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis (AD)
- Atopic Dermatitis
- Asthma
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Asthma · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "ENV-294" as an intervention, largest first.
- A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Enveda TherapeuticsIndustry
NCT07643766 · 200 participants (planned) · Start Jun 29, 2026 · Primary completion Dec 2027
Drug: ENV-294 · For: Atopic Dermatitis
Sites: Encinitas, California; Los Angeles, California; Northridge, California · 9 sites in all
- Study of ENV-294 in Adults With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Enveda TherapeuticsIndustry
NCT07298395 · 105 participants (planned) · Start Dec 22, 2025 · Primary completion Dec 2026
Drug: ENV-294; Placebo · For: Atopic Dermatitis (AD)
Sites: Birmingham, Alabama; Hot Springs, Arkansas; Beverly Hills, California · 32 sites in all
Enveda TherapeuticsIndustry
NCT07301255 · 50 participants (planned) · Start Jan 9, 2026 · Primary completion Dec 2026
Drug: ENV-294; Placebo · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; San Jose, California · 20 sites in all
Enveda TherapeuticsIndustry
NCT07336940 · 9 participants · Start Sep 10, 2025 · Primary completion Jan 13, 2026
Drug: ENV-294 Capsule · For: Atopic Dermatitis (AD)
Sites: Fremont, California; Louisville, Kentucky; College Station, Texas · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis (AD)
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- QY201Phase 33 trials
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Adult Subjects With Non-Segmental Vitiligo, Atopic Dermatitis (AD), Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
- BFB759Phase 32 trials
Bluefin Biomedicine, Inc. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- MH004Phase 32 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Vitiligo, Atopic Dermatitis (AD)
- GS101Phase 31 trial
Jiangsu Genscend Biopharmaceutical Co., Ltd · Atopic Dermatitis (AD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.